Literature DB >> 14691922

Genotypic analysis of pulmonary Langerhans cell histiocytosis.

S Dacic1, C Trusky, A Bakker, S D Finkelstein, S A Yousem.   

Abstract

Reported studies show that the systemic form of Langerhans cell histiocytosis (LCH) is a clonal expansion of Langerhans cells (LC) associated with aberrant expression of several oncogenes or tumor-suppressor genes. LCH of the lung is a heterogenous group of lesions thought to be a reactive rather than neoplastic process. The histogenesis of the LCH of the lung is uncertain, and to date there are no studies investigating its underlying molecular abnormalities. We performed comparative genotypic analysis by using allelic loss (LOH) of polymorphic microsatellite markers associated with tumor suppressor genes. Fourteen cases of formalin-fixed, paraffin-embedded LCH of the lung were studied. Microdissection of a total of 26 nodules from 14 patients and paired reference lung tissue was performed under stereomicroscopic visualization. To evaluate allelic loss, we used a panel of 11 polymorphic microsatellite markers that were situated at or near tumor suppressor genes on chromosomes 1p, 1q, 3p, 5p, 9p, 17p, and 22q. The PCR products were analyzed by using capillary electrophoresis to identify germline heterozygous alleles and LOH. Allelic loss at 1 or more tumor suppressor gene loci was identified in 19 of 24 nodules. The total fractional allelic loss (FAL) ranged from 6% (1q) to 41% (22q), with a mean of 22%. The FAL in individual cases ranged from 0 (7 nodules) to 57% (1 nodule). Fifteen discordant allelic losses at 1 to 3 chromosomal loci were identified in 8 patients with multiple synchronous nodules. Our results show that LOH of tumor suppressor genes is present in the LCH of the lung, and they indicate that the putative tumor suppressor genes situated on chromosomes 9p and 22q may play a role in the development of a subset of the LCH of the lung.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14691922     DOI: 10.1016/j.humpath.2003.07.014

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  Tuberous sclerosis complex 2 loss of heterozygosity in patients with lung disease and cancer.

Authors:  Li Zhang; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Jiro Kato; Mary Haughey; Joseph R Fontana; Vincent C Manganiello; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

2.  Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior.

Authors:  Benoit Hedan; Rachael Thomas; Alison Motsinger-Reif; Jerome Abadie; Catherine Andre; John Cullen; Matthew Breen
Journal:  BMC Cancer       Date:  2011-05-26       Impact factor: 4.430

Review 3.  Pulmonary langerhans cell histiocytosis: case series and literature review.

Authors:  Ping Wei; Hai-Wen Lu; Sen Jiang; Li-Chao Fan; Hui-Ping Li; Jin-Fu Xu
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

4.  Langerhans cell sarcoma with an aberrant cytoplasmic CD3 expression.

Authors:  Zhaodong Xu; Ruth Padmore; Carolyn Faught; Lisa Duffet; Bruce F Burns
Journal:  Diagn Pathol       Date:  2012-09-25       Impact factor: 2.644

5.  Expansion of regulatory T cells in patients with Langerhans cell histiocytosis.

Authors:  Brigitte Senechal; Gaelle Elain; Eric Jeziorski; Virginie Grondin; Natacha Patey-Mariaud de Serre; Francis Jaubert; Kheira Beldjord; Arielle Lellouch; Christophe Glorion; Michel Zerah; Pierre Mary; Mohammed Barkaoui; Jean Francois Emile; Liliane Boccon-Gibod; Patrice Josset; Marianne Debré; Alain Fischer; Jean Donadieu; Frederic Geissmann
Journal:  PLoS Med       Date:  2007-08       Impact factor: 11.069

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.